Addictions, Drug & Alcohol Institute
Addictions, Drug & Alcohol Institute > ADAI Publications

ADAI Publications

1331 publications found

  1. Gordon AJ, Hatch MA, Kropp FB, Liebschutz JM, Mooney LJ, Cochran G. Twenty-five years of the NIDA clinical trials network and the future of addiction research. Journal of Substance Use & Addiction Research 2026: 210140 (in press). [doi: 10.1016/j.josat.2026.210140] PMID: 42893770
  2. Dawson D, Hall W, Goodwin I, Carlini BH, Lubman DI, Hammond D, Freeman TP, Lorenzetti V. Exploring THC labelling preferences to communicate the strength of cannabis products: Insights from U.S. consumers. International Journal of Drug Policy 2026;147:105076. [doi: 10.1016/j.drugpo.2025.105076] PMID: 41442927
  3. Cioffi C, Baloh J, Brunner M, Cheng H, DiFiore E, Davis AD, Fenstemark C, Fisher S, Finlayson R, Franz B, Franz D, Hosseini MA, Rains AN, Schmidt A, Smith C, Vest N, Hartzler B, CTN Implementation Strategies Workgroup. A scoping review of implementation strategies to reduce stigma toward people who use substances in healthcare settings. Journal of Substance Use and Addition Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.210005] PMID: 42069061
  4. Winstead T, Newman A. Syringe Services Program Participants’ Perceptions, Concerns, and Experiences of Medications for Opioid Use Disorder (MOUD). Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, May 2026
  5. Carlini BH, Williams JR, Garrett SB, Hammond D. People with psychotic disorders are the most vulnerable to cannabis adverse health outcomes: A study in WA State, USA. Community Mental Health Journal 2026;62:889-895. [doi: 10.1007/s10597-025-01579-1]
  6. Newman A, Banta-Green CJ. Safer Smoking Supplies – Use, Engagement, and Association with Decreased Injecting in Washington State. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2026.
  7. Hartzler B, Brunner M, Fokuo JK, Ostacher MJ, Pagano A, Rutkowski BA, Vest RA, Masson CL. There and back again: Continuing efforts via regional partnership to promote workforce awareness of scientific advancements in addiction care. Journal of Substance Use and Addiction Treatment 2026 (in press). [doi: 10.1016/j.josat.2026.209905] PMID: 41554458
  8. Leyde S, Bell C, Harris C, Wan C, Nye E, Simon CB, Hoog J, Kennedy AJ, Hartzler B, Tsui JI, Fockele C. “It’s not a one-size-fits-all”: Patient perspectives on contingency management and community reinforcement approach for methamphetamine use disorder in permanent supportive housing. Journal of Health Care for the Poor and Underserved 2026;37(2):705-722. [doi: 10.1353/hpu.2026.a992138] PMID: 42290360
  9. Hartzler B, Peng L, Cooke A, Kunkel L, Stack E, Leahy J, Cook R, Hildebran C, Hoffman K, Verbeck J, Nugent M, Leichtling G, Smith Payne K, McIlveen JW, Korthuis PT. Reason to expand the contingency management workforce: Coaching-to-criterion results for addiction professionals and peer specialists. Substance Use & Addiction Journal 2026;47(2):541-548. [doi: 10.1177/29767342251363007] PMID: 40908764
  10. Iacobelli NP, Estrella L, Owens MD, Bhatraju EP, Gojic AJ, Kennedy D, Chander G, Tsui JI. “You’re doing it because your freedom is on the line”: a qualitative study exploring how people who use opioids and methamphetamine navigate legal involvement and carceral treatment for substance use disorder. Harm Reduction Journal 2026; 23, 30. [doi: 10.1186/s12954-025-01378-7] PMID: 41547813
  11. Salinsky LM, Diaz KC, Fox JL, Panh SM, Ferguson SM. Fentanyl, methamphetamine and polysubstance use differentially affect locomotor sensitisation and social behaviour in rats: Psychedelic treatment reverses social deficits. Addiction Biology 2026;31(3):e70132. [doi: 10.1111/adb.70132]
  12. Whiteside LK, Lovett K, Nye E, Engstrom A, Hall J, Field C, Haegerty P, Palinkas LA, McGovern M, Banta-Green CJ, Zatzick D. Emergency department longitudinal integrated care (EDLINC) study: Protocol for a pragmatic effectiveness randomized clinical trial. Contemporary Clinical Trials 2026 (in press). [doi: 10.1016/j.cct.2026.108400] PMID: 42419503
  13. Carlini BH, Kellum LB, Garrett SB, Williams JR. Cannabis-related problems, adverse events, clinical experiences and barriers to intervening: Perspectives of health care providers in Washington State. Substance Use & Addiction Journal 2026;47(3):852-863. [doi: 10.1177/29767342261426116] PMID: 41910114
  14. Janson S, Newman A, Banta-Green CJ, Glick SN, Tinsley J, Owens MD. Substance use treatment utilization and unmet demand among recently incarcerated syringe services program participants in Washington state. Harm Reduction Journal 2026 (in press). [doi: 10.1186/s12954-026-01512-z]
  15. Bhat A, Curran MC, Lohr MJ, Smith H, Blanchard B, Stoner SA, Grant T, Grote N. Integrating a brief behavioral intervention into case management for mothers with perinatal substance use disorder: Nonrandomized pilot feasibility study. JMIR Formative Research 2025;9:e75132. [doi: 10.2196/75132] PMID: 41468592 PMCID: PMC12753098
  16. Becker SJ, Janssen T, Souza T, Hartzler B, Rash CJ, DiClemente-Bosco K, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): Results of a 28-site cluster-randomized type 3 hybrid trial. Implementation Science 2025;21(1):9. [doi: 10.1186/s13012-025-01473-0] PMID: 41361474 PMCID: PMC12870086
  17. Jha C, Donovan DM. Harm reduction without supportive policing: Experiences of drug users in Nepal. Journal of Social, Behavioral, and Health Sciences 2025;19:1-17. [doi: 10.5590/JSBHS.2025.19.1678]
  18. Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, Toal P, Fegley JP, Meche D, Hankey C, Woodhouse C, Spector A, Dresser L, Moran L, Jelstrom E, Haynes L, Shoptaw S, Hatch MA. Willingness to use oral and long-acting injectable PrEP in substance-using men who have sex with men (SU-MSM) in high HIV incidence Southern U.S. cities: A NIDA Clinical Trials Network study. AIDS and Behavior 2025;29(4):1192-1204. [doi: 10.1007/s10461-024-04594-7]
  19. Owens, MD. Evaluation of the City of Seattle Ordinance 126896 on Controlled Substances: Final Report [to the Seattle Office of Inspector General]. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, December 2025.
  20. Siebert SL, Owens MD, Folk JB, Moore KE. Criminal justice staff’s professional quality of life and interactions with justice-involved individuals: The moderating role of stigma. Deviant Behavior 2025;46(6):803-819. [doi: 10.1080/01639625.2024.2372419] PMID: 40519513